|
BioAnalytica-Genotype S.A. is a biotechnology spin-off company offering state-of-the-art
genetic analysis services. BioAnalytica-Genotype S.A. is a daughter company of
BioAnalytica S.A., a leading provider of molecular analysis technology
infrastructure and consumables.
Headed by Associate Prof. Dr Georgia Bardi, an expert cytogeneticist, the
company offers highest quality diagnostic analysis in classical and molecular
cytogenetics and molecular genetics in the areas of oncology, infectious
diseases and genetic predisposition diseases.
Bioanalytica-Genotype is dedicated to providing a highly reliable service and
scientific excellence. The company holds ISO 15189 accreditation and has a state
of the art equipment laboratory run by highly-skilled scientific personnel.
BioAnalytica-GenoType provides genetic analysis services to healthcare
professionals/organisations, biomedical companies, researchers as well as
pharmaceutical and biotech companies whose products target a specific biological
pathway, or require a diagnostic "eligibility" test to be used as targeted
therapies.
The company has unique expertise in advanced molecular cytogenetic analysis for
the diagnostic and prognostic evaluation of neoplastic diseases, as well as for
aiding the clinician to therapeutic decisions:
The genetic analysis tests offered by BioAnalytica-Genotype S.A include:
- Karyotyping
- High resolution karyotyping for in vitro and in vivo derived malignant cell
population.
- Overall genomic characterisation of haematological malignancies and solid
tumors
- Detection of chromosomal aberrations
- Cytogenetic subclassification of leukemias and lymphomas.
- Detection of minimal residual disease after allogenic bone marrow/stem cell
transplantation.
- Genetic diseases and genetic predisposition on disease conditions
- Reproduction genetics - Male Infertility
- Pharmacogenetics
- Cervical Cancer
- Prostate Cancer
The company offers high quality assurance with low cost, excellent specimen
handling/transport for biological and clinical materials, rapid analysis and
result communication and customization and design of tests depending on specific
needs.
The company's R&D focuses on the design and development of new genetic
tests to be used as an adjunct to classical laboratory services in Oncology. The
company's research activities focus on the recognition of specific sets/panels
of chromosome and/or gene rearrangements that may be used for genetic sub-classification
of tumours within a given diagnostic entity. It is expected that these genetic
panels may be used to distinguish patients eligible or not to certain therapies,
independently of the classical clinicopathologic characteristics of each
individual tumour.
Longer -term R&D activities of the company include the identification of gene
alterations associated with the metastatic potential of various tumour entities,
the genotypic classification of neoplastic disorders, etc.
- Participantion in international projects
- EuroGentest: National representative Cytogenetic EQA scheme
- COST B19: Molecular cytogenetics of solid tumors
- European Leukemia Net: FISH in Multiple Myeloma
- European Cytogenetic Association: Solid tumors studies
Bioanalytica-Genotype S.A. is interested in strategic partnerships with the
following types of partners
- Biotech companies which can manufacture sets of multiple, directly labelled
fluorescence in situ hybridization DNA probes
- Pharmaceutical companies seeking collaborations on pharmacogenomic projects
and clinical trials
- Pharmaceutical companies undertaking follow-up projects in clinical and
pharmaceutical research in Oncology and Hematology
- General Hospitals and Clinics for Oncology, Haematology, Gynaecology,
Cardiology, Pathology, Urology, Orthopaedic, Paediatric, specialties for
diagnostic reasons
- Diagnostic network centres
- Medical Insurance Organizations
- Companies specialised in professional education and training in human genetics,
cancer genetics, cytogenetics and molecular genetics
- Firms seeking consulting in the field of cytogenetics
|
